UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The therapeutic landscape of tauopathies: challenges and prospects

Alzheimer's research & therapy, 2023-10, Vol.15 (1), p.168-17, Article 168

2023

Volltextzugriff (PDF)

NRF2 activation by reversible KEAP1 binding induces the antioxidant response in primary neurons and astrocytes of a Huntington's disease mouse model

Free radical biology & medicine, 2021-01, Vol.162, p.243-254

2021

Volltextzugriff (PDF)

Development of a Series of Aryl Pyrimidine Kynurenine Monooxygenase Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington’s Disease

Journal of medicinal chemistry, 2015-02, Vol.58 (3), p.1159-1183

2015

Volltextzugriff (PDF)

Application of an in Vitro Blood–Brain Barrier Model in the Selection of Experimental Drug Candidates for the Treatment of Huntington’s Disease

Molecular pharmaceutics, 2019-05, Vol.16 (5), p.2069-2082

2019

Volltextzugriff (PDF)

A single-run liquid chromatography mass spectrometry method to quantify neuroactive kynurenine pathway metabolites in rat plasma

Journal of pharmaceutical and biomedical analysis, 2015-03, Vol.107, p.426-431

2015

Volltextzugriff (PDF)

Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO)

Journal of biomolecular screening, 2013-09, Vol.18 (8), p.879-889

2013

Volltextzugriff (PDF)

The Therapeutic Landscape of Tauopathies: Evaluating the Tau Pipeline

Alzheimer's & dementia, 2023-12, Vol.19 (S21), p.n/a

2023

Volltextzugriff (PDF)

Emerging β‑Sheet Rich Conformations in Supercompact Huntingtin Exon‑1 Mutant Structures

Journal of the American Chemical Society, 2017-07, Vol.139 (26), p.8820-8827

2017

Volltextzugriff (PDF)

Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)

Archives of biochemistry and biophysics, 2017-10, Vol.631, p.31-41

2017

Volltextzugriff (PDF)

Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction

Bioorganic & medicinal chemistry, 2020-11, Vol.28 (21), p.115738-115738, Article 115738

2020

Volltextzugriff (PDF)

Design and characterization of mutant and wildtype huntingtin proteins produced from a toolkit of scalable eukaryotic expression systems

The Journal of biological chemistry, 2019-04, Vol.294 (17), p.6986-7001

2019

Volltextzugriff (PDF)

Molecular Mechanism of Stabilizing the Helical Structure of Huntingtin N17 in a Micellar Environment

The journal of physical chemistry. B, 2017-05, Vol.121 (18), p.4713-4721

2017

Volltextzugriff (PDF)

IKBKB reduces huntingtin aggregation by phosphorylating serine 13 via a non-canonical IKK pathway

Life science alliance, 2023-10, Vol.6 (10), p.e202302006

2023

Volltextzugriff (PDF)

Ultrasensitive quantitative measurement of huntingtin phosphorylation at residue S13

Biochemical and biophysical research communications, 2020-01, Vol.521 (3), p.549-554

2020

Volltextzugriff (PDF)

A4 An overview of energy metabolism in huntington’s disease as a therapeutic target

Journal of neurology, neurosurgery and psychiatry, 2016-09, Vol.87 (Suppl 1), p.A2-A2

2016

Volltextzugriff (PDF)

Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington’s Disease

Journal of medicinal chemistry, 2021-04, Vol.64 (8), p.5018-5036

2021

Volltextzugriff (PDF)

Emerging β-sheet rich conformations in super-compact Huntingtin exon-1 mutant structures

Journal of the American Chemical Society, 2017-06, Vol.139 (26), p.8820-8827

2017

Volltextzugriff (PDF)

Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 Interaction

ACS medicinal chemistry letters, 2020-05, Vol.11 (5), p.740-746

2020

Volltextzugriff (PDF)

Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048

Drug metabolism and disposition, 2012-12, Vol.40 (12), p.2297-2306

2012

Volltextzugriff (PDF)

L19 Optimisation of potent, selective and brain penetrant atm inhibitors as potential therapeutic agents for HD

Journal of neurology, neurosurgery and psychiatry, 2016-09, Vol.87 (Suppl 1), p.A96-A96

2016

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Current directions in tau research: Highlights from Tau 2020

The therapeutic landscape of tauopathies: challenges and prospects

NRF2 activation by reversible KEAP1 binding induces the antioxidant response in primary neurons and astrocytes of a Huntington's disease mouse model

Development of a Series of Aryl Pyrimidine Kynurenine Monooxygenase Inhibitors as Potential Therapeutic Agents for the Treatment of Huntington’s Disease

Application of an in Vitro Blood–Brain Barrier Model in the Selection of Experimental Drug Candidates for the Treatment of Huntington’s Disease

Discovery and Structure–Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington’s Disease

A single-run liquid chromatography mass spectrometry method to quantify neuroactive kynurenine pathway metabolites in rat plasma

Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO)

The Therapeutic Landscape of Tauopathies: Evaluating the Tau Pipeline

Emerging β‑Sheet Rich Conformations in Supercompact Huntingtin Exon‑1 Mutant Structures

Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1)

Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction

Design and characterization of mutant and wildtype huntingtin proteins produced from a toolkit of scalable eukaryotic expression systems

The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease

Molecular Mechanism of Stabilizing the Helical Structure of Huntingtin N17 in a Micellar Environment

IKBKB reduces huntingtin aggregation by phosphorylating serine 13 via a non-canonical IKK pathway

Ultrasensitive quantitative measurement of huntingtin phosphorylation at residue S13

A4 An overview of energy metabolism in huntington’s disease as a therapeutic target

Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington’s Disease

Emerging β-sheet rich conformations in super-compact Huntingtin exon-1 mutant structures

Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington’s Disease Models

Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 Interaction

Lead Optimization toward Proof-of-Concept Tools for Huntington’s Disease within a 4‑(1H‑Pyrazol-4-yl)pyrimidine Class of Pan-JNK Inhibitors

Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048

L19 Optimisation of potent, selective and brain penetrant atm inhibitors as potential therapeutic agents for HD

Suchergebnisse filtern